Abstract
Patients with cirrhosis are at risk for adverse drug reactions (ADRs) due to altered pharmacokinetics and pharmacodynamics. We aimed to determine the prevalence of drug prescriptions and the potential safety of these prescriptions in a real-world cohort of patients with cirrhosis.
Original language | English |
---|---|
Pages (from-to) | 539-546 |
Journal | Drug Safety |
Volume | 42 |
Issue number | 4 |
Early online date | 24-Oct-2018 |
DOIs | |
Publication status | Published - Apr-2019 |